Inflammatory resolution: New opportunities for drug discovery

Nature Reviews Drug Discovery

Volumn 3, Issue 5, 2004, Pages 401-416

  Gilroy, Derek W ^a   Lawrence, Toby ^b   Perretti, Mauro ^a   Rossi, Adriano G ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BRADYKININ; CASPASE INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CELL ADHESION MOLECULE; COBROTOXIN; CYCLOSPORIN A; CYTOCHROME P450; CYTOKINE; DELTA12 PROSTAGLANDIN J2; FIBRONECTIN; GLUCOCORTICOID; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE; LIPOCORTIN 1; LIPOXIN A; LIPOXIN B; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; PROSTAGLANDIN J2; SALAZOSULFAPYRIDINE; SUBSTANCE P; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL TRIAL; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INFLAMMATORY DISEASE; LIVER DISEASE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

EID: 2442445450     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1383     Document Type: Review

References (151)

1. Florey, H. W. General Pathology (Lloyd-Luke Ltd, London, 1970).
2. Cotran, R. S., Kumar, V. & Collins, T. (eds) in Robbins Pathologic Basis of Disease Vol. 6 50-88 (W. B. Saunders Company, Philadelphia, 1999).
3. Cotran, R. S., Kumar, V. & Collins, T. (eds) in Robbins Pathologic Basis of Disease Vol. 6 89-112 (W. B. Saunders and Company, Philadelphia, 1999).
4. Dumonde, D. C. & Glynn, L. E. The production of arthritis in rabbits by an immunological reaction to fibrin. Br. J. Exp. Pathol. 43, 373 (1962).
5. Dumonde, D. C. & Glynn, L. E. The reaction of guinea-pigs to autologous and heterologous fibrin implants. J. Pathol. Bacteriol. 90, 649-657 (1965).
6. Weissmann, G., Becher G., Wiedermann, G. & Bernheimer, A. W. Studies on lysozymes. VII. Acute and chronic arthritis produced by intra-articular injections of streptolysin 'S' in rabbits. Am. J. Pathol. 46, 129 (1965).
7. Willoughby, D. A. & Ryan, G. B. Evidence for a possible endogenous antigen in chronic inflammation. J. Pathol. 101, 233-239 (1970).
8. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Amercan College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum. 44, 1496-1503 (2001).
9. Beer H. D., Fassler, R. & Werner, S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam. Horm. 59, 217-239 (2000).
10. Mukherjee, D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol. 63, 817-821 (2002).
11. Antoni, C. & Braun, J. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20, S152-S157 (2002).
12. Urade, Y. & Hayaishi, O. Prostaglandin D synthase: structure and function. Vitam. Horm. 58, 89-120 (2000).
13. Straus, D. S. & Glass, C. K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21, 185-210 (2001).
14. Jiang, C., Ting, A. T. & Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86 (1998).
15. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
16. Nosjean, O. & Boutin, J. A. Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part? Cell Signal. 14, 573-583 (2002).
17. Straus, D. S. et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl Acad. Sci. USA 97, 4844-4849 (2000).
18. Perez-Sala, D., Cernuda-Morollon, E. & Canada, F. J. Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta 12,14-prostaglandin J2. J. Biol. Chem. 278, 51251-51260 (2003).
19. Chen, C. W., Chang, Y. H., Tsi, C. J. & Lin, W. W. Inhibition of IFN-gamma-mediated inducible nitric oxide synthase induction by the peroxisome proliferator-activated receptor gamma agonist, 15-deoxy-delta 12, 14-prostaglandin J2, involves inhibition of the upstream Janus kinase/STAT1 signaling pathway. J. Immunol. 171, 970-988 (2003).
20. Maggi, L. B. Jr et al. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and-independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49, 346-355 (2000).
21. Petrova, T. V., Akama, K. T. & Van Eldik, L. J. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta 12,14-prostaglandin J2. Proc. Natl Acad. Sci. USA 96, 4668-4673 (1999).
22. Bernardo, A., Levi, G. & Minghetti, L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta 12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12, 2215-2223 (2000).
23. Gosset, P. et al. Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J. Immunol. 170, 494349-494362 (2003).
24. Jackson, S. M. et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094-2104 (1999).
25. Pasceri, V., Wu, H. D., Willerson, J. T. & Yeh, E. T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101, 235-238 (2000).
26. Zhang, X., Wang, J. M., Gong, W. H., Mukaida, N. & Young, H. A. Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J. Immunol. 166, 7104-7111 (2001).
27. Zernecke, A., Erl, W., Fraemohs, L., Lietz, M. & Weber, C. Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from IkappaB-alpha kinase inhibition and cell death induction. FASEB J. 17, 1099-1101 (2003).
28. Gilroy, D. W., Tomlinson, A. & Willoughby D. A. Differential effects of inhibitors of cydooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol. 355, 211-217 (1998).
29. Gilroy, D. W. et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med. 5, 698-701 (1999).
30. Gilroy, D. W., Newson, J., Sawmynaden, P., Willoughby, D. A. & Croxtall, J. D. A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J. 18, 480-498 (2004).
31. Gilroy, D. W. et al. Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J. 17, 2269-2271 (2003).
32. Ward, C. et al. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J. Immunol 168, 6232-6243 (2002).
33. Castrillo, A. et al. Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappaB that promotes apoptosis in macrophages. Mol. Cell Biol. 23, 1196-1208 (2003).
34. Li, L. et al. 15-deoxy-delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 276, 38152-38158 (2001).
35. Reference deleted in proof.
36. Setoguchi, K. et al. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108, 1667-1675 (2001).
37. Ando, M. et al. Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin. Am. J. Respir. Cell. Mol. Biol. 28, 582-591 (2003).
38. 2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br. J. Pharmacol. 138, 678-688 (2003).
39. Chatterjee, P. K. et al. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates ischemic acute renal failure. Cardiovasc. Res. 61, 630-643 (2004).
40. Kawahito, Y. et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106, 189-197 (2000).
41. Diab, A. et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515 (2002).
42. Matsuoka, T. et al. Prostaglandin D2 as a mediator of allergic asthma. Science 287, 2013-2017 (2000).
43. H2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. J. Exp. Med. 198, 533-543 (2003).
44. Lee, T. S., Tsai, H. L. & Chau, L. Y. Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-delta 12,14-prostaglandin J2. J. Biol. Chem. 278, 19325-19330 (2003).
45. Ryter, S. W., Otterbein, L. E., Morse, D. & Choi, A. M. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol. Cell. Biochem. 234-235, 249-263 (2002).
46. Willis, D. M. A., Frederick, R. & Willoughby, D. A. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nature Med. 2, 87-90 (1996).
47. Graca-Souza, A. V., Arruda, M. A., de Freitas, M. S., Barja-Fidalgo, C. & Oliveira, P. L. Neutrophil activation by heme: implications for inflammatory processes. Blood 99, 4160-4165 (2002).
48. Alcaraz, M. J., Fernandez, P. & Guillen, M. I. Anti-inflammatory actions of the heme oxygenase-1 pathway. Curr. Pharm. Des. 9, 2541-2551 (2003).
49. Sato, K. et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J. Immunol. 166, 4185-4194 (2001).
50. Hancock, W. W., Buelow, R., Sayegh, M. H. & Turka, L. A. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nature Med. 4, 1392-1396 (1998).
51. Woo, J., Iyer, S., Mori, N. & Buelow, R. Alleviation of graft-versus-host disease after conditioning with cobalt-protoporphyrin, an inducer of heme oxygenase-1. Transplantation 89, 623-633 (2000).
52. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol. 2, 612-619 (2001).
53. Papayianni, A., Serhan, C. N. & Brady, H. R. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol. 156, 2264-2272 (1996).
54. Serhan, C. N., Takano, T., Clish, C. B., Gronert K. & Petasis, N. Aspidn-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogs inhibit neutrophil-madiated changes in vascular permeability. Adv. Exp. Med. Biol. 469, 287-293 (1999).
55. Maddox, J. F. & Serhan, C. N. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183, 137-146 (1996).
56. Maddox, J. F. et al. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272, 6972-6978 (1997).
57. Jozsef, L., Zouki, C., Petasis, N. A., Serhan, C. N. & Filep, J. G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl Acad. Sci. USA 99, 13266-13271 (2002).
58. Bandeira-Melo, C. et al. Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilla. J. Immunol. 164, 1029-1036 (2000).
59. Godson, C. et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667 (2000).
60. Mitchell, S. et al. Lipoxins, aspirin-triggerad epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13, 2497-2507 (2002).
61. Brink, C. et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227 (2003).
62. Bandeira-Melo, C. et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J. Immunol 164, 2267-2271 (2000).
63. Serhan, C. N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204 (2000).
64. Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
65. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R. L. & Serhan, C. N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687 (2003).
66. Brezinski, D. A., Nesto, R. W. & Serhan, C. N. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86, 56-63 (1992).
67. Van Dyke, T. E. & Serhan, C. N. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82, 82-90 (2003).
68. Caria, J. et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 115, 147-156 (1998).
69. Levy B. D. et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nature Med. 8, 1018-1023 (2002).
70. Munger, K. A. et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl Acad. Sci. USA 96, 13375-13380 (1999).
71. Leonard, M. O. et al. 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13, 1657-1662 (2002).
72. Schottelius, A. J. et al. An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol. 189, 7063-7070 (2002).
73. Souza, M. H., de Lima, O. M., Zamuner, S. R., Fiorucci, S. & Wallace, J. L. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G54-G61 (2003).
74. Hughes, J. et al. Neutrophil fate in experimental glomerular capillary injury in the rat. Emigration exceeds lin situ clearance by apoptosis. Am. J. Pathol. 150, 223-234 (1997).
75. Martin, C. et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 19, 583-593 (2003).
76. Bellingan, G. J., Celdwell, H., Howie, S. E., Dransfield, I. & Hasiett, C. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J. Immunol. 157, 2577-2585 (1996).
77. Bellingan, G. J. et al. Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation. J. Exp. Med. 196, 1515-1521 (2002).
78. Savill, J. & Fadok, V. Corpse clearance defines the meaning of cell death. Nature 407, 784-788 (2000).
79. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810-816 (2000).
80. Brunner, T. & Mueller, C. Apoptosis in disease: about shortage and excess. Essays Biochem. 39, 119-130 (2003).
81. Fadok, V. A., Bratton, D. L. & Henson, P. M. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J. Clin. Invest. 108, 957-962 (2001).
82. Savill, J., Dransfield, I., Gregory, C. & Haslett, C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nature Rev. Immunol 2, 965-975 (2002).
83. Ward, C., Dransfield, I., Chilvers, E. R., Haslett, C. & Rossi, A. Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets. Trends Pharmacol. Sci. 20, 503-509 (1999).
84. Giles, K. M., Hart, S. P., Haslett, C., Rossi, A. G. & Dransfield, I. An appetite for apoptotic cells? Controversies and challenges. Br. J. Haematol. 109, 1-12 (2000).
85. Rossi, A. G. et al. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. J. Immunol. 160, 3562-3568 (1998).
86. Liu, Y. et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J. Immunol. 162, 3634-3646 (1999).
87. Giles, K. M. et al. Glucocorticoid augmentation of macrophage capacity for phagocytosis of apoptotic cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high levels of active Rac. J. Immunol. 167, 976-986 (2001).
88. Ren, Y. & Savill, J. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J. Immunol. 154, 2366-2374 (1995).
89. McCutcheon, J. C. et al. Regulation of macrophage phagocytosis of apoptotic neutrophils by adhesion to fibronectin. J. Leukoc., Biol. 64, 600-607 (1998).
90. Hart, S. P., Dougherty, G. J., Haslett, C. & Dransfield, I. CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J. Immunol. 159, 919-925 (1997).
91. Teder, P. et al. Resolution of lung inflammation by CD44. Science 296, 155-158 (2002).
92. Woolley, K. L. et al. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 154, 237-243 (1996).
93. Murphy, F. J., Seery, L. T. & Hayes, I. Therapeutic approaches to the modulation of apoptosis. Essays Biochem. 39, 131-153 (2003).
94. Degterev, A., Boyce, M. & Yuan, J. A decade of caspases. Oncogene 22, 8543-8567 (2003).
95. Eamshaw, W. C., Martins, L. M. & Kaufmann, S. H. Mammallan caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68, 383-424 (1999).
96. Graczyk, P. P. Caspase inhibitors as anti-inflammatory and antiapoptotic agents. Prog. Med. Chem. 39, 1-72 (2002).
97. Iwata, A., Harlan, J. M., Vedder, N. B. & Winn, R. K. The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. Blood 100, 2077-2080 (2002).
98. Natori, S., Higuchi, H., Contreras, P. & Gores, G. J. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl. 9, 278-284 (2003).
99. Hoglen, N. C. et al. Characterization of IDN-6556: a liver-targeted caspase inhibitor J. Pharmacol. Exp. Ther. 23 Jan 2004 [epub ahead of print].
100. Valentino, K. L., Gutierrez, M., Sanchez, R., Winship, M. J. & Shapiro, D. A. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharmacol. Ther. 41, 441-449 (2003).
101. Karin, M. New twists in gone regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93, 487-490 (1998).
102. Ghosh, S., May, M. J. & Kopp, E. B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260 (1998).
103. Khoshnan, A. et al. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J. Immunol. 165, 1743-1754 (2000).
104. Ward, C. et al. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J. Biol. Chem. 274, 4309-4318 (1999).
105. Lawrence, T., Gilroy, D. W., Colville-Nash, P. R. & Willoughby, D. A. Possible new role for NF-kappaB in the resolution of inflammation. Nature Med. 7, 1291-1297 (2001).
106. Ishikawa, H. et al. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50. J. Exp. Med. 187, 985-996 (1998).
107. Bohuslav, J. et al. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J. Clin. Invest. 102, 1645-1652 (1998).
108. Chen, L. W. et al. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nature Med. 9, 575-681 (2003).
109. Munck, A., Guyre, P. M. & Holbrook, N. J. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 5, 25-44 (1984).
110. Flower, R. J., Parente, L., Persico, P. & Salmon, J. A. A comparison of the acute inflammatory response in adrenalectomised and sham-operated rats. Br. J. Pharmacol. 87, 57-62 (1986).
111. Perretti, M., Becherucci, C., Scapigliati, G. & Parente, L. The effect of adrenalectomy on interleukin-1 release in vitro and in vivo. Br. J. Pharmacol. 98, 1137-1142 (1989).
112. Adcock, I. M. Molecular mechanisms of glucocorticosteroid actions. Pulm. Pharmacol. Ther. 13, 115-126 (2000).
113. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270, 286-290 (1995).
114. Buttgereit, F., Burmester, G. R. & Brand, M. D. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol. Today 21, 192-199 (2000).
115. Nissen, R. M. & Yamamoto, K. R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14, 2314-2329 (2000).
116. Flower, R. J. Eleventh Gaddum memorial lecture. Lipocortin and the mechanism of action of the glucocorticoids. Br. J. Pharmacol. 94, 987-1015 (1988).
117. Croxtall, J. D. & Flower, R. J. Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc. Natl Acad. Sci. USA 89, 3571-3575 (1992).
118. De Caterina, R. et al. Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids. J. Appl. Physiol. 75, 2368-2375 (1993).
119. Mancuso, F., Flower, R. J. & Perretti, M. Leukocyte transmigration, but not rolling or adhesion, is selectively inhibited by dexamethasone in the hamster post-capillary venule. Involvement of endogenous lipocortin 1. J. Immunol. 155, 377-386 (1995).
120. Perretti, M., Ahluwalia, A., Harris, J. G., Goulding, N. J. & Flower, R. J. Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J. Immunol. 151, 4306-4314 (1993).
121. Gerke, V. & Moss, S. E. Annexins: from structure to function. Physiol. Rev. 82, 331-371 (2002).
122. Perretti, M. et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nature Med. 8, 1296-1302 (2002).
123. Le, Y., Murphy, P. M. & Wang, J. M. Formyl-peptide receptors revisited. Trends Immunol. 23, 541-548 (2002).
124. Perretti, M. & Gavins, F. N. Annexin 1: an endogenous anti-inflammatory protein. News Physiol. Sci. 18, 60-64 (2003).
125. Parretti, M. et al. Acute inflammatory response in the mouse: exacerbation by immunoneutralization of lipocortin 1. Br. J. Pharmacol. 117, 1145-1154 (1996).
126. Hannon, R. et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1-/-mouse. FASEB J. 17, 253-255 (2003).
127. Yang, Y. H. et al. Modulation of inflammation and response to dexamethasone by Annexin 1 in antigien-induced arthritis. Arthritis Rheum. 50, 976-964 (2004).
128. Perretti, M. The annexin 1 receptor(s): is the plot unraveling? Trends Pharmacol. Sci. 24, 574-579 (2003).
129. Hasko, G. & Cronstein, B. N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25, 33-39 (2004).
130. Sitkovsky, M. V. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem. Pharmacol. 65, 493-501 (2003).
131. Cronstein, B. N., Eberle, M. A., Gruber, H. E. & Levin, R. I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl Acad. Sci. USA 88, 2441-2446 (1991).
132. Cronstein, B. N., Naime, D. & Ostad, E. The antinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675-2682 (1993).
133. Montesinos, M. C. et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48, 240-247 (2003).
134. Xaus, J. et al. IFN-gamma up-ragulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J. Immunol. 162, 3607-3614 (1999).
135. Hasko, G., Deitch, E. A., Szabo, C., Nemeth, Z. H. & Vizi, E. S. Adenosine: a potential mediator of immunosuppression in multiple organ failure. Curr. Opin. Pharmacol 2, 440-444 (2002).
136. Blackburn, M. R. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol. Sci. 24, 66-70 (2003).
137. Catania, A., Gatti, S., Colombo, G. & Lipton, J. M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol. Rev. 56, 1-29 (2004).
138. Fadok, V. A., Bratton, D. L., Frasch, S. C., Warner, M. L. & Henson, P. M. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ. 5, 551-562 (1998).
139. Arur, S. et al. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev. Cell 4, 587-598 (2003).
140. Huynh, M. L., Fadok, V. A. & Henson, P. M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41-50 (2002).
141. Blom, A. B., van Lent, P. L., Holthuysen, A. E. & van den Berg, W. B. Skewed balances in regulation of stimulating and inhibitory FC gamma receptors on macrophages of CIA sensitive mice. Inflamm. Res. 50 (Suppl. 3), S155 (2001).
142. Edenius, C., Haeggstrom, J. & Lindgren, J. A. Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. Biochem. Biophys. Res. Commun. 157, 801-807 (1988).
143. Fiore, S. & Serhan, C. N. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 172, 1451-1457 (1990).
144. Serhan, C. N., Hamberg, M. & Samuelsson, B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl Acad. Sci. USA 81, 5335-5339 (1984).
145. Claria, J. & Serhan, C. N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl Acad. Sci. USA 92, 9475-9479 (1995).
146. McLoughlin, R. M. et al. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J. Clin. Invest. 112, 598-607 (2003).
147. Hurst S. M. et al. II-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14, 705-714 (2001).
148. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403, 103-108 (2000).
149. Castrillo, A., Diaz-Guerra, M. J., Hortelano, S., Martin-Sanz, P. & Bosca, L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20, 1692-1698 (2000).
150. Cemuda-Morollon, E., Pineda-Molina, E., Canada, F. J. & Perez-Sala, D. 15-Deoxy-delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276, 35530-35536 (2001).
151. Bell-Parikh, L. C. et al. Biosynthesis of 15-deoxy delta 12,14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 112, 945-955 (2003).